De Novo device
Ruthless Spine RJB
Ruthless, LLC Dba Ruthless Spine · Intraoperative Surgical Angle Measurement Tool (QWL, Class II) · First FDA decision Jul 14, 2023, newest Sep 17, 2025Scoliosis and spinal deformity
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
De Novo pathway
Device trials
0
Naming "Ruthless"
MAUDE reports
0
Brand "Ruthless", since 2015
PubMed studies
121
Mentioning "Ruthless"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Ruthless Spine RJB
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Ruthless Spine RJB510(k)
K252615 · Decided Sep 17, 2025 · 29 days after receipt
Device type: Intraoperative Surgical Angle Measurement Tool (QWL) · Orthopedic Surgery
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Ruthless", any status and sponsor, newest update first.
No registered device study names "Ruthless".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Ruthless", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QWL
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Ruthless"[tiab]. The summary above synthesizes these.
- Ruthless Health Law.
Charo RA · N Engl J Med · 2020
- Candida: The Ruthless Opportunist.
Rebolo D, Ventura P, Holgado M, et al. · Cureus · 2023Case Reports
- [Antisocial personality disorder].
Repo-Tiihonen E, Hallikainen T · Duodecim · 2016English Abstract, Review
- Ruthless Rufus.
Lowry T · Civ War Times Illus · 2000Biography, Historical Article
- Ruthless reductionism and social cognition.
Bickle J · J Physiol Paris · 2007Review
- Pain--man's ruthless enemy.
Krantz JC · W V Med J · 1979Historical Article
- Cooperative nutrient scavenging is an evolutionary advantage in cancer.
Guzelsoy G, Elorza SD, Ros M, et al. · Nature · 2025Research Support, N.I.H., Extramural
- A ruthless sarcoma of the foot.
Agarwal S · BMJ Case Rep · 2015Case Reports
- Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?
Grabowski , Gaffke L, Pierzynowska K, et al. · Int J Mol Sci · 2022Review
- Mafia and psychopathy.
Schimmenti A, Caprì C, La Barbera D, et al. · Crim Behav Ment Health · 2014
- Marine pollution of a more ruthless kind.
Morton B · Mar Pollut Bull · 2004Editorial
- An Emphasis on Brilliance Fosters Masculinity-Contest Cultures.
Vial AC, Muradoglu M, Newman GE, et al. · Psychol Sci · 2022Research Support, U.S. Gov't, Non-P.H.S.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.